Nevada Organic Phosphate Inc. announced its board is considering a 3-for-1 consolidation of its common shares to enhance capital structure and liquidity as it advances its Murdock Mountain phosphate project. The consolidation aims to better reflect the company's progress in drilling and resource estimation, and to improve access to U.S. capital markets. A shareholder meeting is scheduled for December 30, 2026, to approve the plan, which remains subject to regulatory approval. The company holds about US$2.5 million in cash and is funded to complete its current exploration phase.
Nevada Organic Phosphate's proposed share consolidation is announced as a backdrop to Basic Materials sector activity on Pluang. For readers following Basic Materials, here is Pluang's market snapshot as of Nov 09, 2026 15:41 WIB: out of 83 priced US stocks, 56 rose and 25 fell. Notable movers include GGB at USD 4.38 with a -4.78% change and a typical hold time of 11 days, APD at USD 304.84 down 4.40% with a 62-day hold time, and TX at USD 49.16 down 4.36% with a 25-day hold time.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
